Phaseline

Companies › Voronoi

Voronoi: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VRN101099
HER2 inhibitor
–Phase 1Healthy Adult; HER2-positive Solid TumorsJul 2027
VRN110755
Selective oral EGFR inhibitor targeting activating EGFR mutations and resistance mutations
EGFRPhase 1EGFR-Mutant Non-Small Cell Lung CancerJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07550946VRN101099Phase 1Healthy AdultOtherSep 2026
NCT06806982VRN101099Phase 1HER2-positive Solid TumorsOncologyJul 2027
NCT07699328VRN110755Phase 1EGFR-Mutant Non-Small Cell Lung CancerOncologyJan 2029

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.